S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:CGEN

Compugen - CGEN Stock Forecast, Price & News

$1.44
-0.04 (-2.70%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.38
$1.50
50-Day Range
$1.46
$2.32
52-Week Range
$1.38
$7.48
Volume
1.30 million shs
Average Volume
915,695 shs
Market Capitalization
$98.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75

Compugen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
368.8% Upside
$6.75 Price Target
Short Interest
Bearish
6.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.14mentions of Compugen in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.49) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

CGEN stock logo

About Compugen (NASDAQ:CGEN) Stock

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Compugen Trading Up 1.4 %

Shares of NASDAQ:CGEN opened at $1.48 on Tuesday. The stock has a fifty day simple moving average of $1.83 and a two-hundred day simple moving average of $2.46. Compugen has a 12-month low of $1.39 and a 12-month high of $7.48.

Compugen (NASDAQ:CGEN - Get Rating) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. During the same period in the prior year, the business posted ($0.11) earnings per share. Research analysts predict that Compugen will post -0.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. JMP Securities lowered their target price on Compugen from $8.00 to $4.00 and set a "market outperform" rating for the company in a research note on Monday. Jefferies Financial Group cut Compugen from a "buy" rating to a "hold" rating and set a $2.00 target price for the company. in a research note on Friday. StockNews.com cut Compugen from a "hold" rating to a "sell" rating in a research note on Monday. Finally, Oppenheimer lowered their target price on Compugen from $14.00 to $12.00 and set an "outperform" rating for the company in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $6.75.

Receive CGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

CGEN Stock News Headlines

Compugen (NASDAQ:CGEN) Downgraded by StockNews.com to "Sell"
Compugen Reports Second Quarter 2022 Results
Earnings Preview For Compugen - Benzinga
Compugen (CGEN) Set to Announce Earnings on Thursday
Compugen to Present at Upcoming Industry Conferences
See More Headlines
Receive CGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

CGEN Company Calendar

Last Earnings
8/04/2022
Today
8/09/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CGEN
Employees
73
Year Founded
1993

Price Target and Rating

Average Stock Price Forecast
$6.75
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+368.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-34,200,000.00
Pretax Margin
-560.92%

Debt

Sales & Book Value

Annual Sales
$6 million
Book Value
$1.56 per share

Miscellaneous

Free Float
N/A
Market Cap
$98.52 million
Optionable
Optionable
Beta
2.10

Social Links


Key Executives

  • Dr. Anat Cohen-Dayag Ph.D. (Age 55)
    CEO, Pres & Director
    Comp: $831.63k
  • Mr. Ari Krashin (Age 49)
    Chief Financial & Operating Officer
    Comp: $525.37k
  • Dr. Oliver Froescheis Ph.D. (Age 56)
    Sr. VP of Corp. & Bus. Devel.
    Comp: $447.24k
  • Dr. Zurit Levine (Age 54)
    Sr. VP of Technology Innovation
    Comp: $334.18k
  • Dr. Henry Adewoye M.D. (Age 57)
    Sr. VP & Chief Medical Officer
    Comp: $560.69k
  • Ms. Yvonne Naughton
    Head of Investor Relations & Corp. Communications
  • Mr. Eran Ben Dor
    Gen. Counsel & Corp. Sec.
  • Ms. Dorit Amitay (Age 54)
    VP of HR
  • Dr. Yaron Turpaz M.B.A. (Age 51)
    Ph.D., MBA, Sr. VP & Sr. Advisor of Computational Discovery
  • Rivka Schwartz
    VP Research and Discovery













CGEN Stock - Frequently Asked Questions

Should I buy or sell Compugen stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGEN shares.
View CGEN analyst ratings
or view top-rated stocks.

What is Compugen's stock price forecast for 2022?

4 Wall Street analysts have issued twelve-month target prices for Compugen's stock. Their CGEN share price forecasts range from $2.00 to $12.00. On average, they predict the company's stock price to reach $6.75 in the next year. This suggests a possible upside of 387.4% from the stock's current price.
View analysts price targets for CGEN
or view top-rated stocks among Wall Street analysts.

How has Compugen's stock performed in 2022?

Compugen's stock was trading at $4.30 at the start of the year. Since then, CGEN shares have decreased by 67.8% and is now trading at $1.3850.
View the best growth stocks for 2022 here
.

When is Compugen's next earnings date?

Compugen is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our CGEN earnings forecast
.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) issued its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. During the same quarter last year, the business earned ($0.11) earnings per share.

What is Anat Cohen-Dayag's approval rating as Compugen's CEO?

2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Who are Compugen's major shareholders?

Compugen's stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (15.76%), Nikko Asset Management Americas Inc. (0.00%), Sumitomo Mitsui Trust Holdings Inc. (0.00%), Antonetti Capital Management LLC (0.76%), Rothschild Investment Corp IL (0.00%) and Defender Capital LLC. (0.00%).

How do I buy shares of Compugen?

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $1.39.

How many employees does Compugen have?

Compugen employs 73 workers across the globe.

When was Compugen founded?

Compugen was founded in 1993.

How can I contact Compugen?

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The official website for the company is www.cgen.com. The biotechnology company can be reached via phone at (723) 765-8585, via email at ir@cgen.com, or via fax at 972-3765-8555.

This page (NASDAQ:CGEN) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.